175 related articles for article (PubMed ID: 24752661)
21. Characteristics of IDH-mutant gliomas with non-canonical IDH mutation.
Poetsch L; Bronnimann C; Loiseau H; Frénel JS; Siegfried A; Seizeur R; Gauchotte G; Cappellen D; Carpentier C; Figarella-Branger D; Eimer S; Meyronet D; Ducray F;
J Neurooncol; 2021 Jan; 151(2):279-286. PubMed ID: 33205355
[TBL] [Abstract][Full Text] [Related]
22. [IDH1/2 mutations in gliomas].
Nobusawa S; Yokoo H
Brain Nerve; 2011 Dec; 63(12):1378-86. PubMed ID: 22147457
[TBL] [Abstract][Full Text] [Related]
23. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.
Mellai M; Piazzi A; Caldera V; Monzeglio O; Cassoni P; Valente G; Schiffer D
J Neurooncol; 2011 Nov; 105(2):345-57. PubMed ID: 21643842
[TBL] [Abstract][Full Text] [Related]
24. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
25. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
[TBL] [Abstract][Full Text] [Related]
26. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
27. Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies.
de Vries NA; Bruggeman SW; Hulsman D; de Vries HI; Zevenhoven J; Buckle T; Hamans BC; Leenders WP; Beijnen JH; van Lohuizen M; Berns AJ; van Tellingen O
Clin Cancer Res; 2010 Jul; 16(13):3431-41. PubMed ID: 20472681
[TBL] [Abstract][Full Text] [Related]
28. Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival.
Yao Y; Chan AK; Qin ZY; Chen LC; Zhang X; Pang JC; Li HM; Wang Y; Mao Y; Ng HK; Zhou LF
PLoS One; 2013; 8(6):e67421. PubMed ID: 23840696
[TBL] [Abstract][Full Text] [Related]
29. Glioma is formed by active Akt1 alone and promoted by active Rac1 in transgenic zebrafish.
Jung IH; Leem GL; Jung DE; Kim MH; Kim EY; Kim SH; Park HC; Park SW
Neuro Oncol; 2013 Mar; 15(3):290-304. PubMed ID: 23325864
[TBL] [Abstract][Full Text] [Related]
30. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
[TBL] [Abstract][Full Text] [Related]
31. IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas.
Qi ST; Yu L; Lu YT; Ou YH; Li ZY; Wu LX; Yao F
Oncol Rep; 2011 Dec; 26(6):1479-85. PubMed ID: 21874255
[TBL] [Abstract][Full Text] [Related]
32. Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1.
Ma D; Zhan D; Fu Y; Wei S; Lal B; Wang J; Li Y; Lopez-Bertoni H; Yalcin F; Dzaye O; Eberhart CG; Laterra J; Wilson MA; Ying M; Xia S
Cancer Lett; 2021 Oct; 517():35-45. PubMed ID: 34098063
[TBL] [Abstract][Full Text] [Related]
33. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?
Kloosterhof NK; Bralten LB; Dubbink HJ; French PJ; van den Bent MJ
Lancet Oncol; 2011 Jan; 12(1):83-91. PubMed ID: 20615753
[TBL] [Abstract][Full Text] [Related]
34. A vaccine targeting mutant IDH1 induces antitumour immunity.
Schumacher T; Bunse L; Pusch S; Sahm F; Wiestler B; Quandt J; Menn O; Osswald M; Oezen I; Ott M; Keil M; Balß J; Rauschenbach K; Grabowska AK; Vogler I; Diekmann J; Trautwein N; Eichmüller SB; Okun J; Stevanović S; Riemer AB; Sahin U; Friese MA; Beckhove P; von Deimling A; Wick W; Platten M
Nature; 2014 Aug; 512(7514):324-7. PubMed ID: 25043048
[TBL] [Abstract][Full Text] [Related]
35. IDH1
Han X; Zhou H; Sun W; Hou L; Wang Y; Wang H; Lv Z; Xue X
Sci Rep; 2023 Nov; 13(1):19659. PubMed ID: 37952042
[TBL] [Abstract][Full Text] [Related]
36. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.
Pellegatta S; Valletta L; Corbetta C; Patanè M; Zucca I; Riccardi Sirtori F; Bruzzone MG; Fogliatto G; Isacchi A; Pollo B; Finocchiaro G
Acta Neuropathol Commun; 2015 Jan; 3():4. PubMed ID: 25849072
[TBL] [Abstract][Full Text] [Related]
37. Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
Yang R; Zhao Y; Gu Y; Yang Y; Gao X; Yuan Y; Xiao L; Zhang J; Sun C; Yang H; Qin J; Li J; Zhang F; Zhang L; Ye J
Oncogene; 2020 Oct; 39(40):6340-6353. PubMed ID: 32855525
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.
Takano S; Kato Y; Yamamoto T; Kaneko MK; Ishikawa E; Tsujimoto Y; Matsuda M; Nakai K; Yanagiya R; Morita S; Tsuboi K; Matsumura A
J Neurooncol; 2012 Jul; 108(3):361-73. PubMed ID: 22396072
[TBL] [Abstract][Full Text] [Related]
39. IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.
Zeng A; Hu Q; Liu Y; Wang Z; Cui X; Li R; Yan W; You Y
Oncotarget; 2015 Oct; 6(30):30232-8. PubMed ID: 26338964
[TBL] [Abstract][Full Text] [Related]
40. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
Mukasa A; Takayanagi S; Saito K; Shibahara J; Tabei Y; Furuya K; Ide T; Narita Y; Nishikawa R; Ueki K; Saito N
Cancer Sci; 2012 Mar; 103(3):587-92. PubMed ID: 22136423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]